United Therapeutics Corporation
UTHR
$536.00
-$0.12-0.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.68% | 14.47% | 16.15% | 15.25% | 21.35% |
| Total Depreciation and Amortization | 18.07% | 24.06% | 31.30% | 40.80% | 36.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 344.96% | -2.15% | 12.64% | 37.31% | 47.09% |
| Change in Net Operating Assets | -2,830.77% | 165.94% | 54.58% | 122.73% | 103.99% |
| Cash from Operations | 17.64% | 36.92% | 24.03% | 44.11% | 35.70% |
| Capital Expenditure | -111.16% | -82.10% | -31.88% | -24.59% | -6.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.64% | -101.38% | -157.41% | -136.07% | 265.93% |
| Cash from Investing | -232.14% | -176.72% | -282.99% | -303.89% | 157.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.00% | -50.00% | -133.33% | -100.00% | -300.00% |
| Issuance of Common Stock | 14.37% | -22.64% | -10.41% | 57.74% | 53.06% |
| Repurchase of Common Stock | -0.93% | -0.92% | 97.90% | 98.41% | -7,234.78% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -325.93% | -325.93% | -325.93% | 100.00% | 0.00% |
| Cash from Financing | 8.35% | -3.94% | 64.10% | 75.14% | -10,444.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.62% | -147.92% | -17.68% | 636.82% | 98.58% |